AntriaBio (OTC:ANTB) said today that it filed an investigational new drug application with the FDA for its once-weekly basal insulin. If the Louisville, Colo.-based company wins approval from the FDA, it plans to launch a Phase I clinical trial of AB101 in patients with Type I diabetes. The first-in-human study is slated to evaluate the […]
Clinical Trials
Novartis, IBM Watson collab to optimize care for patients with advanced breast cancer
Novartis (NYSE:NVS) said today that it inked a deal with IBM Watson Health to optimize care and improve outcomes for patients with advanced breast cancer. The 2 companies plan to develop a “cognitive solution” using real-world patient data and analytics to better understand expected outcomes of breast cancer treatment options and develop personalized treatment plans […]
Medtech stories we missed this week: June 2, 2017
From Implandata receiving CE Marking to Inolife eyeing up-listing, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. Dextera seeks expanded indications for MicroCutter 5/80 stapler Dextera Surgical announced in a June 1 press release that it has filed a 510(k) with the FDA for its MicroCutter 5/80 stapler. The […]
Cingulate moves controlled-release ADHD drug to human testing
Cingulate Therapeutics said this week that it began a proof-of-concept trial for its controlled-release attention deficit/hyperactivity disorder drug. The 4-week clinical trial is being conducted by its development partner, Bio-Images Drug Delivery. The trial enrolled healthy volunteers to evaluate the pharmacokinetic behavior of CTX-1301, including the body’s absorption, distribution, metabolism and excretion of the drug. […]
BioCorRx partners with virtual reality center for naltrexone implant study
BioCorRx (OTC:BICX) said today that it partnered with the Virtual Reality Medical Center to conduct a study on the company’s long-lasting naltrexone implant. BioCorRx’s recovery program consists of a long-lasting implant that delivers an opioid antagonist, naltrexone, which reduces physical cravings for alcohol and opioids. The recovery service also has a counseling program specifically designed […]
Philips, Illumina to launch precision medicine cancer program with Navican
Royal Philips (NYSE:PHG) and Intermountain Healthcare company Navican inked an agreement today to launch a precision health informatics solution aimed at improving outcomes for late stage cancer patients. The program is slated to leverage Navican‘s TheraMap Precision Cancer Care services and Philips’ IntelliSpace Genomics platform, which uses Illumina‘s next-gen genomic sequencing technologies. At Utah-based Intermountain Healthcare’s […]
Chiltern acquires Integrated Development Associates
Contract research organization Chiltern announced today that it is expanding its Japanese and Asian presence through its purchase of Integrated Development Associates. Financial terms of the deal were not disclosed. IDA has staff in Japan, Korea and Southeast Asia – and offers opportunities to integrate the region into global drug development, according to Chiltern. IDA’s expertise includes […]
Nanoparticles: An industry buzzword meets reality
Young startups backed by nanoparticle tech face a world hurdles before reaching the clinic. It’s been decades since the first innovations with nanotechnology – and experts are asking, “Where are all the drugs?” It’s been more than 20 years since the FDA approved the first nanoparticle drug, Doxil. At the time, nanoparticles were heralded as a […]
Lamellar Biomedical launches dry-eye trial
Lamellar Biomedical said today that the 1st patients were enrolled in its trial evaluating Lamelleye for the treatment of moderate to severe dry-eye disease. Lamelleye uses the Scotland-based company’s Lamellasome technology to mimic the actions of serous lamellar bodies and regulate interfaces between tissues and external environments. The trial is slated to compare Lamelleye to […]
Medtronic launches opioid-induced respiratory depression study
Medtronic (NYSE:MDT) said today that it’s starting a large study on the effect of pulse oximetry and capnography in opioid-induced respiratory depression, using its Capnostream device. The 1,650-patient Prodigy study aims to create a tool to score the risk of OIRD in patients being treated with opioids for pain, using Capnostream’s continuous pulse oximetry and capnography monitoring […]